Volume 13, Issue 52 (9-2023)                   NCMBJ 2023, 13(52): 45-57 | Back to browse issues page

XML Persian Abstract Print


Islamic Azad University Tehran Medical Sciences, Tehran,Iran , bpoopak@gmail.com
Abstract:   (565 Views)

Aim and Background: The level of an immune response inhibitory enzyme, called indoleamine 2,3-dioxygenase (IDO), and the activity of Treg cells increase in some patients with cancer and acute leukemias such that it can lead to the inhibition of immune responses. Therefore, the very aim of the present study was to evaluate the regulatory T cells (CD4 + / FOXP3 +) and the level of the IDO expression in acute leukemias using flow cytometry and Real-Time PCR.  Materials and Methods: This study used bone marrow samples taken from  30 patients with acute lymphoid leukemia (ALL), and 20 healthy individuals. Then, the level of the IDO expression and the percentage of Treg cells were evaluated using flow cytometry and Real-Time PCR. The results revealed that the percentage of Treg in the total lymphocytes, T and Th in the ALL group was significantly higher than that of the normal groups the respectively (P <0.001). Results: In addition, the level of the IDO expression in the normal group was significantly lower than that of the ALL group (P= 0.016). Conclusion: The level of the IDO expression in the ALL groups was significantly higher than the normal group. Moreover, there was a positive and non-significant relationship between the level of the IDO expression and the percentages of Treg cells in the ALL group. Therefore, it seems necessary to conduct more studies for the behavior of this leukemia in the expression of IDO enzyme and the percentage of Treg cells and their relationship with each other.

 
Full-Text [PDF 586 kb]   (172 Downloads)    
Type of Study: Research Article | Subject: Physiology
Received: 2023/03/14 | Accepted: 2023/09/23 | Published: 2023/10/21

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.